CMTA_2020_Annual_Report

…Target Discovery Discovery 1A Discovery Research Tools Preclinical Phase1 Phase2 Phase3 10 11 32+ Research Partners 50+ Research Projects $17M+ in Research Funding D E M Y E L I…

The_2018_CMTA_Report_35th_Anniversary_Edition

…picture of how prevalent CMT actually is. • Influences and perhaps changes the direction CMT research will take. • Stimulates research interest and attracts more research funds. • Speeds up…

The_2018_CMTA_Report_35th_Anniversary_Edition

…picture of how prevalent CMT actually is. • Influences and perhaps changes the direction CMT research will take. • Stimulates research interest and attracts more research funds. • Speeds up…

Help_for_Today_2-2017

research within the CMT community, and it is the only CMT-specific patient advocacy organization in the United States strategically aligned with the National Institutes of Health Rare Disease Clinical Research

Help_for_Today_2-2017

research within the CMT community, and it is the only CMT-specific patient advocacy organization in the United States strategically aligned with the National Institutes of Health Rare Disease Clinical Research

2018_CMTA_Annual_Report_2

…is a non-profit organization dedicated to finding a cure for CMT. The CMTA’s Strategy to Accelerate Research (STAR) program brings top researchers together with pharmaceutical and biotechnology partners and patients…

2017_Fall_CMTA_Report

…to walk, run, dance and enjoy life to the fullest.” CMT1A research is part of CMTA’s Strategy to Accelerate Research (STAR) program that puts top researchers together with pharmaceutical partners—and…

CMTAreportSpring2022

…inform a more general therapeutic strategy for dominant CMT2E. All the CMTA’s research efforts are consolidated under the banner of STAR—which brings together the world’s largest network of biotech research

2017_Fall_CMTA_Report

…to walk, run, dance and enjoy life to the fullest.” CMT1A research is part of CMTA’s Strategy to Accelerate Research (STAR) program that puts top researchers together with pharmaceutical partners—and…